See related Avastin inj[癌思停 注射劑] information
製造商 Roche
代理/經銷商 Roche
成份 Bevacizumab
適應症 In combination with irinotecan/5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin as 1st-line treatment of metastatic carcinoma of the colon or rectum. In combination with 5-fuorouracil/leucovorin/oxaliplatin for treatment of metastatic carcinoma of the colon or rectum which previous fluoropyrimidine therapy is ineffective. In combination with paclitaxel is for 1st-line treatment of HER2 (-) metastatic breast cancer. Monotherapy for treatment of glioblastoma after relapse. In combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer.
用量 Metastatic colorectal cancer 1st-line treatment: 5 mg/kg once every 2 weeks. 2nd-line treatment: 10 mg/kg every 2 weeks or 15 mg/kg once every 3 weeks. Metastatic breast cancer & malignant glioma (WHO grade IV) 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks. Advanced, metastatic or recurrent non small cell lung cancer (NSCLC) 7.5 mg/kg every 3 weeks in addition to cisplatin-based chemotherapy or 15 mg/kg every 3 weeks in addition to carboplatin-based chemotherapy. Continue treatment until progression of underlying disease. Initial dose should be given over 90-min infusion following chemotherapy; 2nd dose over 60-min infusion & all subsequent doses over 30-min infusion before or after chemotherapy.
過量 View Avastin[癌思停] overdosage for action to be taken in the event of an overdose.
美國食品藥物管理局之懷孕等級
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
禁忌 Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies; untreated CNS metastases.
注意事項 Increased risk for development of GI perforation. Discontinue treatment in patients with tracheoesophageal fistula or any Grade 4 fistula, grade 3 or 4 bleeding. Congenital bleeding diathesis, acquired coagulopathy or in patients receiving full dose of anticoagulants. Recent pulmonary hemorrhage/hemoptysis. Monitoring of BP during therapy. History of Reversible Posterior Leukoencephalopathy Syndrome (RPLS). History of arterial thromboembolism or age > 65 years. Discontinued in patients with life-threatening (Grade 4) pulmonary embolism, patients with Grade ≤ 3 need to be closely monitored. Patients with clinically significant CV disease or preexisting CHF. Should not be initiated for at least 28 days following major surgery or until the surgical wound is fully healed. Treatment should be withheld in patients who experience wound healing complication or undergoing selective surgery. Discontinue treatment in patients with grade 4 proteinuria. Pregnancy & lactation.
不良反應 GI perforations, tumour-associated & mucocutaneous hemorrhage, arterial & venous thromboembolism, HTN, fatigue, asthenia, diarrhea, abdominal pain. Dyspepsia, taste perversion, headache, eye disease, dysnea, nasal bleeding, rhinitis, GI disturbances, skin disorders, proteinuria, asthenia, pain.
View ADR Monitoring Website[參閱藥物不良反應監測表格]
交互作用 [Click for Avastin[癌思停] detailed prescribing infomation]
View more drug interactions with Avastin[癌思停]
使用上注意 For caution against possible variation of physical aspect of medicine... click to view Avastin[癌思停] detailed prescribing infomation
儲存 View Avastin[癌思停] storage conditions for details to ensure optimal shelf-life.
描述 View Avastin[癌思停] description for details of the chemical structure and excipients (inactive components).
作用 View Avastin[癌思停] mechanism of action for pharmacodynamics and pharmacokinetics details.
本商品之市售規格
劑型 包裝 圖片
Avastin 注射劑 Avastin 100 mg/4 mL x 4 mL x 1's
Avastin 400 mg/16 mL x 1's
Manufacturer: Roche
Distributor: Roche
